Printer Friendly

NORTH AMERICAN BIOLOGICALS, INC. CREATES HIVIG PRODUCTION FACILITY; PILOT LAB CONSTRUCTED; COLLECTION CENTER SEEKS SPECIAL LICENSE

 MIAMI, May 24 /PRNewswire/ -- North American Biologicals, Inc. ("NABI")(NASDAQ: NBIO) today announced that its Immune Therapy division has built a pilot laboratory to produce clinical trial quantities of HIVIG(tm), NABI's proprietary formulation of HIV Immune Globulin, according to cGMPs complying with Food and Drug Administration regulations. The company has also applied for a special FDA license for its Coconut Grove, Fla. plasma collection site to qualify the facility to collect and process HIV-positive plasma. In addition, the company has initiated an outreach program to encourage HIV-positive individuals to donate plasma for formulation into HIVIG(tm).
 NABI's goal is to have HIVIG(tm) subjected to clinical trials to test its effectiveness in preventing the transmission of AIDS from HIV- positive mothers to unborn infants. Early data indicate that HIVIG(tm), an experimental immune globulin, may be effective for this indication. NABI acquired all the rights and assets associated with HIVIG(tm) from Abbott Laboratories last year. HIVIG(tm) has orphan drug status.
 "We are presently well prepared to supply HIVIG(tm) for clinical trial use, and we are very excited at the possibility that this product could play a role in stopping the spread of AIDS from mother to child," said David J. Gury, chairman, president and CEO of NABI.
 HIVIG(tm) is prepared from the plasma of HIV-antibody-positive donors who are healthy and have a strong immune response to the virus. The plasma is extensively tested and processed to inactivate any resident virus. The antibodies within the plasma are then purified and concentrated to prepare for final administration into patients.
 Immune Globulin products are a growing segment of the pharmaceutical industry, with market forecasts in excess of $1 billion by 1997. Derived from human plasma, immune globulins are used to immunize recipients against infectious diseases, viral or bacterial, to which they have been exposed.
 NABI's Immune Therapy division was founded in 1992 to develop and commercialize immune globulin products for the diagnosis and therapy of immune disorders. Its first commercial product is H-BIG(R), prescribed for the prevention of Hepatitis B following exposure.
 North American Biologicals, Inc., headquartered in Miami, is one of the world's largest independent providers of human blood plasma elements to the health care industry, and is dedicated to improving the quality of human life by providing plasma and plasma-based products for the diagnosis and therapy of immune disorders.
 -0- 5/24/93
 /CONTACT: David J. Gury, president, Alfred J. Fernandez, chief financial officer of North American Biologicals, Inc., 305-625-5303; Marcia A. Kean, executive vice president, Chris Taylor, account executive of Feinstein Partners Inc., 617-577-8110/
 (NBIO)


CO: North American Biologicals, Inc. ST: Florida IN: MTC SU:

SM -- NE001 -- 1540 05/24/93 09:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 24, 1993
Words:450
Previous Article:COMPUTER NETWORK TECHNOLOGY CORPORATION ANNOUNCES LETTER OF INTENT TO ACQUIRE ULTRA NETWORK TECHNOLOGIES, INC.
Next Article:AOX AND DRAGON SYSTEMS ANNOUNCE AGREEMENT FOR INTEGRATION OF SPEECH RECOGNITION INTO DSP-BASED PC PRODUCTS
Topics:


Related Articles
ABBOTT LABORATORIES TRANSFERS HIVIG TO NORTH AMERICAN BIOLOGICALS, INC.
NORTH AMERICAN BIOLOGICALS, INC. REPORTS FIRST QUARTER 1993 RESULTS; RETURNS TO PROFITABILITY
NORTH AMERICAN BIOLOGICALS, INC. ALLOWED EUROPEAN PATENT FOR HIVIG: PRODUCT MAY PREVENT HIV TRANSMISSION TO INFANTS
NORTH AMERICAN BIOLOGICALS RECEIVES FDA LICENSE FOR NEW BIOMEDICAL CENTER - $1.7 MILLION IN PLASMA SHIPMENTS FROM OKLAHOMA SITE UNDERWAY
NABI ESTABLISHES SCIENTIFIC ADVISORY BOARD WITH IMMUNOLOGISTS, VIROLOGISTS AND PEDIATRICIANS FROM LEADING MEDICAL INSTITUTIONS
NORTH AMERICAN BIOLOGICALS COMPLETES ACQUISITION OF MAJOR PLASMA COMPANY
NORTH AMERICAN BIOLOGICALS, INC. GAINS FIRST-EVER LICENSE TO COLLECT SPECIALTY PLASMA IN GERMANY
NORTH AMERICAN BIOLOGICALS TO ACQUIRE NETWORK OF U.S. PLASMA COLLECTION CENTERS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR SECOND QUARTER 1995
NORTH AMERICAN BIOLOGICALS, INC. EXPANDS GERMAN PLASMA COLLECTION OPERATIONS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters